Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1985-10-25
1988-02-16
Marantz, Sidney
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 29, 436519, 436530, 436548, 436813, 436824, G01N 33554, G01N 33574, G01N 33577
Patent
active
047255382
ABSTRACT:
Method to detect and/or determine the presence of cancer cells in mammals, including humans, and to monitor the progress of treatment for cancer. A human protein marker, the assay-marker, has been ascertained of the molecular weight 70,000-74,000, which is secreted by cancer cells at levels 10-fold or greater than that observed with normal cells. An assay is described where the assay-marker or an antigenically analogous protein, the analog-marker, is used to prepare antibodies to the assay-marker. The antibodies are then reacted with blood or serum samples to determine the level of the assay-marker in the sample. Thus, the assay essentially comprises (1) providing an antibody to the protein described above (2) reacting the antibody of step 1 with the sample to be tested and (3) measuring the level of the reacted antibody to detect and/or determine the presence and/or quantity of cancer cells.
REFERENCES:
patent: 4469787 (1984-09-01), Woods
Elias, L. et al., J. Biol. Chem., 260 (11), 7023-7028 (1985).
"Differential Effect of Plasma Fractions from Normal and Tumour-Bearing Rats on Nuclear RNA Restriction", Nature, vol. 256, Aug. 7, 1975; Dorothy E. Schumm et al.
"A Major Phosphoprotein Marker for Neoplastic Transformation of Fibroplastic and Epithelial Cells", B. B. Asch et al.; Cold Spring Harbor Conferences on Cell Proliferation, vol. 9, Growth of Cells in Hormonally Defined Media, 1982, Cold Spring Harbor Laboratory.
"Absence of the Cancer-Associated Factor with a Molecular Weight of 60,000 from the Plasma of Patients with a Spectrum of Nonneoplastic Conditions", Dorothy E. Schumm et al.; Cancer Research 44, 401-406, Jan. 1984.
"Understanding Breast Cancer/Phosphoproteins as Markers of Neoplastic Progression in Mammary Cells; Bonnie B. Asch, et al., AMC Cancer Research Center and Hospital, Denver, CO., Marcel Dekker, Inc. 1983.
"Putative Transformation-Dependent Proteins in the Blood Plasma of Tumor-Bearing Rats and Cancer Patients"; Dorothy E. Schumm et al., Cancer Research 42, pp. 4964-4969, Dec., 1982.
"Transformation-Specific Secreted Proteins", Donald R. Senger et al.; Cold Spring Harbor Symposia on Quantitative Biology, vol. XLIV, 1980 Cold Spring Harbor Lab.
"A Secreted Phosphoproteinmarker for Neoplastic Transformation of both Epithelial and Fibroblastic Cells", Donald R. Senger et al., Reprinted from Nature, vol. 302, No. 5910, pp. 714-715. Apr. 1983.
"Transformed Mammalian Cells Secrete Specific Proteins and Phosphoproteins", Donald R. Senger et al., Cell, vol. 16, 885-893, Apr. 1979.
"Transformation-Specific Secreted Phosphoproteins"/Macmillan Journals Ltd. 1980, Donald R. Senger et al., Nature, vol. 286, No. 5773, pp. 619-621, Aug. 7, 1980.
Marantz Sidney
The Beth Israel Hospital Association
LandOfFree
Method of assaying the presence of cancer cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of assaying the presence of cancer cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of assaying the presence of cancer cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2220927